London
· Delayed Price · Currency is GBP · Price in SEK Egetis Therapeutics AB Statistics
Total Valuation
Egetis Therapeutics AB has a market cap or net worth of GBP 162.31 million. The enterprise value is 161.01 million.
| Market Cap | 162.31M |
| Enterprise Value | 161.01M |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +29.11% |
| Shares Change (QoQ) | -1.64% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 210.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 7.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.85 |
| EV / Sales | 32.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.35.
| Current Ratio | 0.98 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.59 |
Financial Efficiency
Return on equity (ROE) is -81.30% and return on invested capital (ROIC) is -42.12%.
| Return on Equity (ROE) | -81.30% |
| Return on Assets (ROA) | -34.12% |
| Return on Capital (ROIC) | -42.12% |
| Revenue Per Employee | 128,075 |
| Profits Per Employee | -602,273 |
| Employee Count | 28 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 415.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.66% in the last 52 weeks. The beta is 1.43, so Egetis Therapeutics AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -0.66% |
| 50-Day Moving Average | 5.80 |
| 200-Day Moving Average | 5.74 |
| Relative Strength Index (RSI) | 47.90 |
| Average Volume (20 Days) | 5,220 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Egetis Therapeutics AB had revenue of GBP 4.99 million and -23.49 million in losses. Loss per share was -0.08.
| Revenue | 4.99M |
| Gross Profit | -10.27M |
| Operating Income | -22.32M |
| Pretax Income | -23.48M |
| Net Income | -23.49M |
| EBITDA | -22.05M |
| EBIT | -22.32M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 9.56 million in cash and 8.25 million in debt, giving a net cash position of 1.30 million.
| Cash & Cash Equivalents | 9.56M |
| Total Debt | 8.25M |
| Net Cash | 1.30M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 23.44M |
| Book Value Per Share | 0.08 |
| Working Capital | -191,264 |
Cash Flow
| Operating Cash Flow | -15.89M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -205.60% |
| Operating Margin | -446.83% |
| Pretax Margin | -470.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Egetis Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.11% |
| Shareholder Yield | -29.11% |
| Earnings Yield | -14.47% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Egetis Therapeutics AB has an Altman Z-Score of -1.3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.3 |
| Piotroski F-Score | n/a |